{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:25:48Z","timestamp":1775795148480,"version":"3.50.1"},"reference-count":168,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health (Ricerca Corrente)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The treatment of Non Small Cell Lung Cancer (NSCLC) has been revolutionised by the introduction of targeted therapies. With the improvement of response and frequently of overall survival, however, a whole new set of adverse events emerged. In fact, due to the peculiar mechanism of action of each one of the tyrosine kinase inhibitors and other targeted therapies, every drug has its own specific safety profile. In addition, this safety profile could not fully emerge from clinical trials data, as patients in clinical practice usually have more comorbidities and frailties. Cardiotoxicity is a well-known and established adverse event of anti-cancer therapies. However, only recently it has become a central topic for targeted therapies in NSCLC, due to the unknown real range and frequency. Management of this toxicity begins with prevention, and must balance the need of continuing an effective anticancer treatment versus low risk of even fatal events and the preservation of long-term quality of life. The aim of this review is to summarise the current knowledge focusing on currently used targeted therapies in NSCLC.<\/jats:p>","DOI":"10.3390\/ijms26020554","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T06:25:54Z","timestamp":1736490354000},"page":"554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2490-0556","authenticated-orcid":false,"given":"Sara","family":"Torresan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"},{"name":"Department of Medicine (DME), University of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1364-5478","authenticated-orcid":false,"given":"Martina","family":"Bortolot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"},{"name":"Department of Medicine (DME), University of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"De Carlo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8045-6838","authenticated-orcid":false,"given":"Elisa","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-7399","authenticated-orcid":false,"given":"Brigida","family":"Stanzione","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-0335","authenticated-orcid":false,"given":"Alessandro","family":"Del Conte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-2338","authenticated-orcid":false,"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.cllc.2023.09.007","article-title":"Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study","volume":"25","author":"Kobat","year":"2024","journal-title":"Clin. Lung Cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2313824","DOI":"10.1001\/jamanetworkopen.2023.13824","article-title":"Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non-Small Cell Lung Cancer in Taiwan","volume":"6","author":"Chang","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","article-title":"Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches","volume":"33","author":"Lamore","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/10781552221077417","article-title":"Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: Are real-world studies the way forward?","volume":"29","author":"Kobat","year":"2023","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, Y., Deng, X., Qiu, Q., and Wan, M. (2024). Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1431023"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11864-019-0657-y","article-title":"QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics","volume":"20","author":"Chandrasekhar","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 9.","DOI":"10.3390\/cancers9050052"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.critrevonc.2017.07.003","article-title":"Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going","volume":"117","author":"Russo","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","article-title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","volume":"18","author":"John","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"viii500","DOI":"10.1093\/annonc\/mdy292.011","article-title":"Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: A combined analysis of two phase III randomized controlled trials","volume":"29","author":"Thein","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2017-0425","article-title":"FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"ref_17","first-page":"2029","article-title":"Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2217\/fon-2019-0324","article-title":"ASTRIS: A Global Real-World Study of Osimertinib in >3000 Patients with EGFR T790M Positive Non-Small-Cell Lung Cancer","volume":"15","author":"Wu","year":"2019","journal-title":"Future Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12268","DOI":"10.3390\/ijms131012268","article-title":"Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics","volume":"13","author":"Hervent","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac Safety of Osimertinib: A Review of Data","volume":"39","author":"Ewer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.toxlet.2024.05.005","article-title":"Transcriptomics coupled with proteomics reveals osimertinib-induced myocardial mitochondrial dysfunction","volume":"397","author":"Yang","year":"2024","journal-title":"Toxicol. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jtho.2017.05.016","article-title":"Cardiac Dysfunction Caused by Osimertinib","volume":"12","author":"Oyakawa","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, P., Tian, X., Wang, G., Jiang, E., Li, Y., and Hao, G. (2023). Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1177003"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131ra50","DOI":"10.1126\/scitranslmed.3003623","article-title":"Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome","volume":"4","author":"Lu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40959-015-0006-7","article-title":"Cardiac safety of afatinib: A review of data from clinical trials","volume":"1","author":"Ewer","year":"2015","journal-title":"Cardio-Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00280-013-2286-7","article-title":"Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors","volume":"72","author":"Molife","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100594","DOI":"10.1016\/j.currproblcancer.2020.100594","article-title":"QT interval prolongation related to afatinib treatment in a patient with metastatic non\u2013small-cell lung cancer","volume":"44","author":"Demircan","year":"2020","journal-title":"Curr. Probl. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ramos, G.E., Caglevic, C., Bulnes, J.F., Panay, S.E., Zapata, M.I., Daniele, A.J., and Rodr\u00edguez, M.E. (2022). Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1060813"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, H., Wang, Y., Li, J., He, Z., Boswell, S.A., Chung, M., You, F., and Han, S. (2023). Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med., 21.","DOI":"10.1186\/s12916-023-02838-2"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, Y., Qiu, Q., Deng, X., and Wan, M. (2024). EGFR-TKIs\u2014Induced cardiotoxicity in NSCLC: Incidence, evaluation, and monitoring. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1426796"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1536\/ihj.22-583","article-title":"Gefitinib Increases the Incidence of QT Prolongation in Patients with Non-Small Cell Lung Cancer","volume":"64","author":"Maimaitituersun","year":"2023","journal-title":"Int. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion\u2013Mutated Non\u2013Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtho.2023.11.020","article-title":"Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sun, R., Ning, Z., Qin, H., Zhang, W., Teng, Y., Jin, C., Liu, J., and Wang, A. (2024). A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55829-5"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107509","DOI":"10.1016\/j.lungcan.2024.107509","article-title":"Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201","volume":"190","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer: Results From LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_44","first-page":"100224","article-title":"Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies","volume":"2","author":"Jang","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.21037\/tlcr-23-160","article-title":"Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer","volume":"12","author":"Park","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/j.jtho.2021.01.1241","article-title":"P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer","volume":"16","author":"Cho","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br. J. Cancer."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study\u2606","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_56","unstructured":"(2024, October 19). Alectinib Versus Crizotinib in Untreated Asian Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALESIA): A Randomised Phase 3 Study\u2014The Lancet Respiratory Medicine. Available online: https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(19)30053-0\/abstract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in Resected ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase\u2013Positive Non\u2013Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_59","first-page":"2091","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial","volume":"18","author":"Yang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_67","first-page":"100332","article-title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion\u2013Positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a KRASG12C Mutation","volume":"387","author":"Riely","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion\u2013positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial\u2606","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: Final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non\u2013Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non\u2013Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"a001115","DOI":"10.1101\/mcs.a001115","article-title":"ALK: A tyrosine kinase target for cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Liu, Y., Chen, C., Rong, C., He, X., and Chen, L. (2022). Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.858279"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14740338.2023.2234279","article-title":"Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: An analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"22","author":"Wang","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40264-023-01300-9","article-title":"Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)","volume":"46","author":"Niimura","year":"2023","journal-title":"Drug Saf."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14796694.2024.2370239","article-title":"Cardiovascular toxicity of anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: A network meta-analysis","volume":"14","author":"Cai","year":"2024","journal-title":"Future Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2021.08.014","article-title":"ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis","volume":"161","author":"Cirne","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ho, C.C., Wu, S.L., Tsai, H.Y., and Chou, C.Y. (Int. J. Clin. Pharm., 2024). Predictors of bradycardia in non-small-cell lung cancer patients receiving anaplastic lymphoma kinase inhibitors in a teaching hospital: A retrospective cohort study, Int. J. Clin. Pharm., preprint.","DOI":"10.21203\/rs.3.rs-4389888\/v1"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of alectinib on cardiac electrophysiology: Results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaccao.2021.01.009","article-title":"Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability","volume":"3","author":"Ye","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer Treatment-Induced Arrhythmias","volume":"10","author":"Buza","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaccao.2022.09.006","article-title":"Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up","volume":"5","author":"Pruis","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1759-7714.14769","article-title":"High incidence and reversible bradycardia events following alectinib initiation","volume":"14","author":"Yuan","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40262-023-01284-w","article-title":"Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor","volume":"62","author":"Gupta","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"S1893","DOI":"10.1016\/j.jtho.2017.09.658","article-title":"P1.01-004 Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK + NSCLC","volume":"12","author":"Camidge","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical Management of Adverse Events Associated with Lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Li, H., Wang, C., and Guo, C. (2024). Post-marketing safety of lorlatinib: A real-world study based on the FDA adverse event reporting system. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1385036"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/cncr.28089","article-title":"Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients","volume":"119","author":"Weickhardt","year":"2013","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-017-0020-z","article-title":"Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity","volume":"3","author":"Zhang","year":"2017","journal-title":"Cardio-Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/CIRCRESAHA.116.303975","article-title":"Control of Cardiac Repolarization by Phosphoinositide 3-Kinase Signaling to Ion Channels","volume":"116","author":"Ballou","year":"2015","journal-title":"Circ. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/cpt.956","article-title":"Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development","volume":"104","author":"Cleary","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular Pathways: ROS1 Fusion Proteins in Cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14740338.2023.2182284","article-title":"Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: A meta-analysis of randomized control trials","volume":"22","author":"Zhao","year":"2023","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"A14702","DOI":"10.1161\/circ.146.suppl_1.14702","article-title":"Abstract 14702: The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis","volume":"146","author":"Thakre","year":"2022","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","article-title":"Factors associated with sinus bradycardia during crizotinib treatment: A retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007)","volume":"5","author":"Ou","year":"2016","journal-title":"Cancer Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2013.04.027","article-title":"Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes","volume":"272","author":"Doherty","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/15548627.2023.2259216","article-title":"Inhibition of PRKAA\/AMPK (Ser485\/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion","volume":"20","author":"Xu","year":"2024","journal-title":"Autophagy"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/s41591-024-03008-4","article-title":"Entrectinib in ROS1-positive advanced non-small cell lung cancer: The phase 2\/3 BFAST trial","volume":"30","author":"Peters","year":"2024","journal-title":"Nat. Med."},{"key":"ref_108","first-page":"100746","article-title":"Entrectinib-Induced Myocarditis and Acute Heart Failure responding to steroid treatment: A case report","volume":"5","author":"Majeed","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e243946","DOI":"10.1136\/bcr-2021-243946","article-title":"Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer","volume":"14","author":"Fonseca","year":"2021","journal-title":"BMJ Case Rep. CP"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"ytad324","DOI":"10.1093\/ehjcr\/ytad324","article-title":"Entrectinib-induced Brugada phenocopy in a patient with metastatic non-small cell lung cancer","volume":"7","author":"Kubota","year":"2023","journal-title":"Eur. Heart J.\u2014Case Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s13691-023-00620-y","article-title":"Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: A case report and literature review","volume":"12","author":"Futamura","year":"2023","journal-title":"Int. Cancer Conf. J."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Liguori, V., Gaio, M., Zinzi, A., Cagnotta, C., Riccardi, C., Docimo, G., and Capuano, A. (2023). The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092538"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1316","article-title":"1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)","volume":"35","author":"Planchard","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw. Open."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries","volume":"10","author":"Guha","year":"2021","journal-title":"Cancer Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1016\/j.annonc.2023.09.2249","article-title":"1115P Comparison of efficacy and toxicity of dabrafenib\/trametinib versus vemurafenib\/cobimetinib therapy in routine medical practice: Eight years of BRAF\/MEK inhibitor use in routine clinical practice","volume":"34","author":"Piejko","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors","volume":"192","author":"Bronte","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1093\/emboj\/19.23.6341","article-title":"The MEK1\u2013ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice","volume":"19","author":"Bueno","year":"2000","journal-title":"EMBO J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaccao.2022.07.009","article-title":"Cellular and Molecular Mechanisms of MEK1 Inhibitor\u2013Induced Cardiotoxicity","volume":"4","author":"Beck","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ajmg.a.61270","article-title":"Costello syndrome: Clinical phenotype, genotype, and management guidelines","volume":"179","author":"Gripp","year":"2019","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_124","first-page":"e1","article-title":"Noonan syndrome: Genetic and clinical update and treatment options","volume":"93","author":"Carcavilla","year":"2020","journal-title":"An. Pediatr\u00eda Engl. Ed."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"69477","DOI":"10.18632\/oncotarget.17704","article-title":"BRAF\/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/ATVBAHA.107.158154","article-title":"CD47: A new target in cardiovascular therapy","volume":"28","author":"Isenberg","year":"2008","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e2300030","DOI":"10.1200\/PO.23.00030","article-title":"Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non\u2013Small Cell Lung Cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/10915818211022965","article-title":"Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer","volume":"40","author":"Ishida","year":"2021","journal-title":"Int. J. Toxicol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Regua, A.T., Najjar, M., and Lo, H.W. (2022). RET signaling pathway and RET inhibitors in human cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.932353"},{"key":"ref_130","first-page":"e15441","article-title":"Into the Unknown: A Case of New-Onset Cardiomyopathy in a Patient Treated With Recently Approved Tyrosine Kinase Inhibitor, Pralsetinib","volume":"13","author":"Papaila","year":"2021","journal-title":"Cureus"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I\/II Trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Hou, Y., Ren, X., Chen, Y., and Wang, Y. (2014). Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. Expert. Opin. Drug Saf., 1\u20139.","DOI":"10.1080\/14740338.2024.2392003"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Jie, Q., Li, Y., Jing, L., Chen, J., and Li, Y. (2024). Adverse event profile differences between pralsetinib and selpercatinib: A real-world study based on the FDA adverse events reporting system. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1424980"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"H\u00f8jer Wang, L., Wehland, M., Wise, P.M., Infanger, M., Grimm, D., and Kreissl, M.C. (2023). Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032312"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer Therapy\u2013Related Hypertension: A Scientific Statement From the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","article-title":"A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations","volume":"10","author":"Santarpia","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","article-title":"MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes","volume":"24","author":"Mazieres","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib Treatment in Patients With MET Exon 14\u2013Skipping Non\u2013Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14\u2013Mutated or MET-Amplified Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"115018","DOI":"10.1016\/j.taap.2020.115018","article-title":"The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies","volume":"398","author":"Me","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Yang, Z., Wang, W., Wang, X., and Qin, Z. (2021). Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.741451"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Park","year":"2023","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: A systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2021.09.005","article-title":"NTRK fusions in lung cancer: From biology to therapy","volume":"161","author":"Harada","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tcm.2014.10.005","article-title":"Ischemic heart disease in women: A focus on risk factors","volume":"25","author":"Mehta","year":"2015","journal-title":"Trends. Cardiovasc. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2020.10.021","article-title":"Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction","volume":"153","author":"Kunimasa","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Lavaud, P., Bortolot, M., Zullo, L., O\u2019reilly, D., Naidoo, J., Mountzios, G., Mercier, O., Hendriks, L.E.L., and Remon, J. (2024). Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies. Cancers, 16.","DOI":"10.3390\/cancers16162779"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Kalra, A., and Rashdan, S. (2023). The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1158417"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00262-023-03429-z","article-title":"Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations","volume":"72","author":"Shimoda","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_155","unstructured":"L\u00f3pez-Fernandez, T., and Dent, S.F. (2024, October 28). Strategies for Risk Stratification and Cardiovascular Toxicity Prevention in Patients with Cancer. Available online: https:\/\/www.escardio.org\/Councils\/Council-for-Cardiology-Practice-(CCP)\/Cardiopractice\/strategies-for-risk-stratification-and-cardiovascular-toxicity-prevention-in-pat."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.recesp.2020.11.014","article-title":"Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC","volume":"74","author":"Mitroi","year":"2021","journal-title":"Rev. Esp. Cardiol. Engl. Ed."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/2047487319874900","article-title":"The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology","volume":"28","author":"Anselmi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"192","DOI":"10.31083\/j.rcm2407192","article-title":"Sacubitril\/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice","volume":"24","author":"Cheng","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature21505","article-title":"Cardiovascular disease: Commonality with cancer","volume":"543","author":"Tall","year":"2017","journal-title":"Nature"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e021165","DOI":"10.1161\/JAHA.121.021165","article-title":"Validation of the 2016 ASE\/EACVI Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction","volume":"10","author":"Enait","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.amjcard.2017.02.008","article-title":"Frequency of Left Ventricular End-Diastolic Volume\u2013Mediated Declines in Ejection Fraction in Patients Receiving Potentially Cardiotoxic Cancer Treatment","volume":"119","author":"Sukpraphrute","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.117.027930","article-title":"Early Myocardial Strain Changes During Potentially Cardiotoxic Chemotherapy May Occur as a Result of Reductions in Left Ventricular End-Diastolic Volume","volume":"135","author":"Jordan","year":"2017","journal-title":"Circulation"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review","volume":"63 Pt A","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_165","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur. Heart J.\u2014Cardiovasc. Imaging"},{"key":"ref_167","unstructured":"Poku, N., Ramalingam, S., Andres, M.S., Gevaert, S., and Lyon, A.R. (2024, October 28). Monitoring and Treatment of Cardiovascular Complications During Cancer Therapies. Part II: Tyrosine Kinase Inhibitors. Available online: https:\/\/www.escardio.org\/Councils\/Council-for-Cardiology-Practice-(CCP)\/Cardiopractice\/monitoring-and-treatment-of-cardiovascular-complications-during-cancer-therapies-Part-2."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/curroncol28010029","article-title":"Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib","volume":"28","author":"Blais","year":"2021","journal-title":"Curr. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:26:28Z","timestamp":1759919188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":168,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26020554"],"URL":"https:\/\/doi.org\/10.3390\/ijms26020554","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}